Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...
Management holds 11th Annual ESG Investor Virtual Event on December 9 at 10 am. NVS ).webcasts.com/starthere.jsp?ei=1689776&tp_key=9312b9a422′ target= ‘_blank’; rel=’nofollow’>Webcast Link Discover ...
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...
Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...
Novartis (NVS) announced “positive,” longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major ...
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...